Studies on α(v)β3/ligand interactions using a [3H]SK and F-107260 binding assay

Molecular Pharmacology

Volumn 50, Issue 3, 1996, Pages 529-537

  Wong, Angela ^a,b   Hwang, Shing Mei ^a   Mcdevitt, Patrick ^a   Mcnulty, Dean ^a   Stadel, Jeffrey M ^a   Johanson, Kyung ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTAPEPTIDE; SKF 107260; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL ADHESION; CHICKEN; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BLOOD PLATELETS; CELL ADHESION; CHICKENS; CHROMATOGRAPHY, AFFINITY; FEMALE; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; OSTEOCLASTS; OSTEOPONTIN; OSTEOSARCOMA; PEPTIDES, CYCLIC; PLACENTA; PLATELET AGGREGATION INHIBITORS; PREGNANCY; RADIOLIGAND ASSAY; RATS; RECEPTORS, VITRONECTIN; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SIALOGLYCOPROTEINS; TRITIUM;

EID: 9544258252     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cheresh, D. A., and R. C. Spiro. Biosynthetic, and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma attachment to vitronectin, fibrinogen and von-Willebrand factor. J. Biol. Chem. 262:17703-17711 (1987).
2. Horton, M. Current status review: vitronectin receptor, tissue specific expression or adaptation to culture? Int. J. Exp. Pathol. 71:741-759 (1990).
3. Davies, J., J. Warwick, N. Totty, R. Philp, M. Helfrich, and M. Horton. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J. Cell Biol. 109:1817-1826 (1989).
4. 3 for angiogenesis. Science (Washington D. C.) 264:569-571 (1994).
5. 3 in smooth muscle migration to osteopontin in vitro. J. Clin. Invest. 95:713-724 (1995).
6. Fisher, J. E., M. P. Caulfield, M. Sato, H. A. Quartuccio, R. J. Gould, V. M. Garsky, G. A. Rodan, and M. Rosenblatt. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD) containing protein. Endocrinology 132:1411-1413 (1993).
7. 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164 (1994).
8. Horton, M. A., M. L. Taylor, T. R. Arnett, and M. H. Helfrich. Arg-Gly-Asp peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclast. Exp. Cell Res. 195:368-375 (1991).
9. Pytela, R., M. D. Pierschbacher, M. H. Ginsberg, E. F. Plow, and E. Ruoslahti. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science (Washington D. C.) 231: 1559-1562 (1986).
10. Coller, B. S., J. D. Folts, S. R. Smith, L. E. Scudder, and R. Jordan, Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockage of GPIIb/IIIa. Circulation 80:1766-1774 (1989).
11. Cheresh, D. A., and J. R. Harper. Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130 kDa α subunit. J. Biol. Chem. 262:1434-1437 (1987).
12. Horton, M. A., D. Lewis, K. McNulty, J. A. S. Pringle, and T. J. Chambers. Monoclonal antibodies to osteoclastomas (giant cell bone tumours): definition of osteoclast-specific antigens. Cancer Res. 45:5663-5669 (1985).
13. 3. J. Bone Mineral Res. 7:345-351 (1992).
14. + ATPases. Proc. Natl. Acad. Sci. USA 89:6257-6261 (1992).
15. Lundeen, J. E., and J. H. Gordon, in Receptor Binding in Drug Research (R. O'Brien, ed.). Dekker, New York (1986).
16. 50) of an enzyme reaction. Biochem. Pharmacol. 22:3099-3108 (1973).
17. Horton, M. A., E. L. Dorey, S. A. Nesbitt, J. Samanen, F. Ali, A. Stadel, J. M. Nichols, R. Greig, and M. H. Helfrich. Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis. J. Bone Mineral Res. 8:239-247 (1993).
18. Fitzgerald, L. A., B. Steiner, S. C. Rall, Jr., S. S. Lo, and D. R. Phillips. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. J. Biol. Chem. 262:3936-3939 (1987).
19. Rosa, J.-P., P. F. Bray, O. Gayet, G. I. Johnston, R. G. Cook, K. W. Jackson, M. A. Shuman, and R. P. McEver. Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17. Blood 72:593-600 (1988).
20. Fitzgerald, L. A., M. Poncz, B. Steiner, S. C. Rall, J. S. Bennett, and D. R. Phillips. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor α-subunits and platelet glycoprotein IIb. Biochemistry 26:8158-8165 (1987).
21. Suzuki, S., W. S. Argraves, H. Arai, L. R. Languino, M. D. Pierschbacher, and E. Ruoslahti. Amino acid sequence of the vitronectin receptor α subunit and comparative expression of adhesion receptor mRNAs. J. Biol. Chem. 262:14080-14085 (1987).
22. Suzuki, S., W. S. Argraves, R. Pytela, H. Arai, T. Kruisius, M. D, Pierschbacher, and E. Ruoslahti. cDNA, and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc. Natl. Acad. Sci. USA 83:8614-8618 (1987).
23. Bossy, B., and L. F. Reichardt. Chick integrin α subunit molecular analysis reveals high conservation of structural domains and association with multiple β subunits in embryo fibroblasts. Biochemistry 29:10191-10198 (1990).
24. Munson, P. J., and D. Rodbard. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:220-239 (1980).
25. Alig, L., A. Edenhofer, P. Hadvary, M. Hurzeler, D. Knopp, M. Muller, B. Steiner, A. Trzeciak, and T. Weller. Low molecular weight, non-peptide fibrinogen receptor antagonists. J. Med. Chem. 35:4393-4407 (1992).
26. Ku, T. W., F. E. Ali, L. S. Barton, J. W. Bean, W. E. Bondinell, J. L. Burgess, J. F. Callahan, R. R. Calvo, L. Chen, D. S. Eggleston, J. G. Gleason, W. F. Huffman, S. M. Hwang, D. R. Jakes, C. B. Karash, R. M. Keenan, K. D. Kopple, W. H. Miller, K. A. Newlander, A. Nichols, M. F. Parker, C. E. Peishoff, J. M. Samanen, I. Uzinskas, and J. W. Venslavsky. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of highly constrained cyclic RGD peptides. J. Am. Chem. Soc. 115:8861-8862 (1993).
27. Hartman, G. D., M. S. Egbertson, W. Halczenko, W. L. Laswell, M. E. Duggan, R. L. Smith, A. M. Naylor, P. D. Manno, R. J. Lynch, G. Zhang, C. T. -C. Chang, and R. J. Gould. Non-peptide fibrinogen receptor antagonists 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35:4640-4642 (1992).
28. Conforti, G., A. Zanetti, I. Pasquali-Ronchetti, D. Quaglino, Jr., P. Neyroz, and E. Dejana. Modulation of vitronectin receptor binding by membrane lipid composition. J. Biol. Chem. 265:4011-4019 (1990).
29. 3 and its ligand. J. Biol. Chem. 266:19543-19550 (1991).
30. 1 intergrins. J. Biol. Chem. 269:20233-20238 (1994).
31. 3. FEBS Lett. 358:179-181 (1995).
32. 3 subunit. Proc. Natl. Acad. Sci. USA 86:5415-5418 (1989).
33. 3 integrin is present on human osteoclast. Exp. Cell Res. 205:345-352 (1993).
34. Sato, M., V. Garsky, R. J. Majeska, T. A. Einhorn, J.Murray, A. H. Tashjian, Jr., and R. J. Gould. Structure-activity studies of the s-echistatin inhibition of bone resorption. J. Bone Mineral Res. 9:1441-1449 (1994).
35. Zambonin-Zallone, A., A. Teti, M. Grano, A. Rubianacci, M. Abbadini, M. Gaboli, and P. C. Marchisio. Immunohistochemical distribution of extracellular receptors in human osteoclasts: α integrin colocalized with vinculin and talin in the podosomes of osteoclastoma giant cells. Exp. Cell Res. 182:645-652 (1989).
36. 3 integrin submit in rat osteoclasts in situ. J. Bone Miner. Res. 8:403-414 (1993).
37. Cheresh, D. A., and F. G. Klier. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J. Cell Biol. 102:1887-1897 (1986).
38. Burns, G. F., C. M. Lucas, G. W. Krissansen, J. A. Werkmeister, D. B. Scanlon, R. J. Simpson, and M. A. Vadas. Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells. J. Cell Biol. 107:1225-1230 (1988).
39. 3-integrins. J. Biol. Chem. 269:960-967 (1994).
40. 3-dependent ligand binding. J. Cell Biol. 123:485-496 (1993).
41. Gresham, H. D., S. P. Adams, and E. J. Brown. Ligand binding specificity of the leukocyte response integrin expressed by human neutrophils. J. Biol. Chem. 267:13895-13902 (1992).